Does Regeneron Pharmaceuticals, Inc. (REGN) Present Much Upside ?

It is interesting to note that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is active and made a solid movement in the last trading day. Now trading with a market value of 32.36B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For REGN, the company currently has 1.02 billion of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 9.37 billion in total assets, balanced by 2.81 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Regeneron Pharmaceuticals, Inc. (REGN) saw 539.37 million in free cash flow last quarter, representing a quarterly net change in cash of 206.76 million. Perhaps most importantly where cash movements are concerned, the company saw about 618.74 million in net operating cash flow.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 1.51 billion in total revenues. That represents a quarterly year/year change in revenues of 0.14 in sequential terms, the REGN saw sales decline by -0.04.

But what about the bottom line? After all, that’s what really matters in the end. Regeneron Pharmaceuticals, Inc. (REGN) is intriguing when broken down to its core data. The cost of selling goods last quarter was 151.26 million, yielding a gross basic income of 1.36 billion. For shareholders, given the total diluted outstanding shares of 114.91 million, this means overall earnings per share of 4.16. Note, this compares with a consensus analyst forecast of 4.38 in earnings per share for its next fiscal quarterly report.

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 17.80 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 14.40. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Regeneron Pharmaceuticals, Inc..

Previous ArticleNext Article

Related Post

DryShips Inc. (DRYS) Makes An Interesting Case Rig... DryShips Inc. (NASDAQ:DRYS) is in the highlights and many would want to know whether now might be a good time for it to present much upside. Now tradi...
Critical Comparison: Enbridge Energy Partners, L.P... Enbridge Energy Partners, L.P. (NYSE:EEP) and Dominion Energy Midstream Partners, LP (NYSE:DM) are the two most active stocks in the Oil & Gas Pip...
It’s worth it to have a look at Alibaba Grou... Alibaba Group Holding Limited (NYSE:BABA) is an interesting stock at present. Now trading with a market value of 492.30B, the company has a mix of cat...
Looking at the Big Picture for Skechers U.S.A., In... It is interesting to note that Skechers U.S.A., Inc. (NYSE:SKX) is active and made a solid movement in the last trading day. Now trading with a market...
Alnylam Pharmaceuticals, Inc. (ALNY) vs. Akcea The... Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Akcea Therapeutics, Inc. (NASDAQ:AKCA) are the two most active stocks in the Biotechnology industry ba...